Symposium 10: The changing landscape of drug development and early phase Clinical Trials
Tracks
Track 2
| Friday, December 12, 2025 |
| 11:00 AM - 1:00 PM |
Details
Early-phase clinical trials remain a pivotal way of capturing pharmacological data in humans. However, as technologies evolve, the previous ways of developing drugs and conducting clinical trials may not be suitable for newer therapies. This symposium will discuss some of the new technologies that are being encountered in current early phase trials – including the use of psychedelics, monoclonal antibodies and siRNAs - the difficulties encountered with designing and evaluating such trials, and the novel ways of capturing useful outcome data for progression of study. The symposium will have speakers with interests in clinical trials with specific examples of “new” study designs for emerging therapies (eg, psychedelics, monoclonal antibodies, siRNAs) and will finish with a discussion about the technical aspects of modern study design and the future of study design for emerging therapies.
Speaker
Dr Tom Polasek
Clinical Pharmacologist
CMAX Clinical Research; Monash University
Novel Therapeutic Modalities
Biography
Prof Jonathan Brett
St. Vincent's Hospital, Sydney; NSW Poisons information Centre; UNSW
The challenges of conducting psychedelic clinical trials
Biography
Dr Millie Wang
Research Physician, NZCR
New Zealand Clinical Research
Challenges of conducting trials with Complement inhibitors
Biography
Prof Sepehr Shakib
University of Adelaide; Northern Adelaide Local Health Network; CMAX Clinical Research
Technical aspects of modern early phase study design – what does the future of early phase clinical studies look like?
Biography
Chair
Angela Molga
Head of Unit, Clinical Pharmacology
Central Adelaide Local Health Network
